MIT scientists discover an amino acid that helps the gut heal itself
Researchers at MIT have decoded a biochemical mechanism that underpins the gut's capacity to repair itself. The study, published in the journal Cell on 19 May 2026, documents that a cysteine-derivative amino acid -- taurocholic acid (TCA) -- directly triggers the division and differentiation of stem cells in the gut wall. The finding is regarded as one of the most important basic-science results to appear in gut microbiota research over the past decade.
The study's senior author, Professor Omer Yilmaz of MIT's Biomedical Engineering Department, said, 'we have long known that the gut is a rapidly regenerating tissue -- it renews on average every 4-5 days -- but we could not identify the molecular triggers of this renewal. We have shown that the cysteine derivative taurocholic acid functions as the central signalling molecule of stem-cell renewal.'
In experiments on mice, scientists measured that artificially raising taurocholic acid levels accelerated gut healing, while lowering them caused delays. In particular, after inflammation -- for example in gut models exposed to chemical damage -- TCA-supplemented mice completed epithelial (lining) repair 40-50 hours faster than the control group. This corresponds to an increase in the gut's regeneration rate of roughly two-thirds.
The mechanism is linked to the Wnt signalling pathway. The study showed that TCA directly activates the Wnt pathway through a receptor specifically functioning on LGR5+ stem cells. Although the role of the Wnt pathway in gut regeneration was previously known, how the signalling line was triggered remained unclear; what the study shows is that microbiome-produced TCA is the natural switch of that signalling line.
For clinical applications, the finding opens the door to a potential new therapeutic approach for inflammatory bowel disease (IBD). Ulcerative colitis and Crohn's disease affect approximately 7 million people worldwide; existing therapies (immunosuppressants, biologics, corticosteroids) generally focus on suppressing inflammation, while there is no method that directly accelerates gut healing. A TCA-based therapy could play a complementary role to existing treatments.
Dr Mehmet Aslan, an IBD specialist at Crohn and Foundation Hospital (no direct connection to the MIT researchers), said, 'the finding is clinically exciting, but it should be noted that the move from mouse to human will require a long road. TCA operates with rather different kinetics in the human body; it is continuously recycled by the liver and the gallbladder. Human trials may be on a 3-5-year time horizon.' Aslan also stressed that this article does not substitute for individual medical advice and that IBD patients must manage their treatment together with specialists.
The finding is an important turning point for microbiome research. Hundreds of studies on the microbiome's effect on gut health have been published in the past decade, but most remained at the level of statistical correlation. The MIT study has, for the first time, shown the direct molecular effect of a microbiome-produced metabolite (TCA) on epithelial stem cells at a mechanistic level. This establishes a new 'mechanistic-picture' standard for future microbiome research.
The study also examined the effect of different diets on TCA production. Diets rich in oily fish (omega-3) and high in fibre (fruit and vegetables) were observed to raise TCA levels, while processed-food and sugar-heavy diets lowered them. This provides molecular support for the view -- already advanced by clinical nutritionists -- that a Mediterranean-style diet is beneficial for gut health. But how much TCA change is produced by which diet depends on individual microbiome composition.
Among the study's incidental findings was that a particular intestinal Lactobacillus strain plays a central role in TCA production. This Lactobacillus strain can reach the human gut through fermented dairy products (especially kefir and yogurt). The marketing claims of probiotic supplements have historically been supported by weak scientific evidence; but the link of this specific strain with a TCA-mediated gut-healing mechanism offers a concrete biological basis for kefir and yogurt consumption.
The MIT study was conducted as part of a large gut-microbiome programme funded by the NIH and the Bill and Melinda Gates Foundation, with results published in Cell. The research team announced its intention to launch a joint clinical programme with Boston Children's Hospital and Massachusetts General Hospital over the next two years to develop TCA-based therapeutic compounds. This article is for science-news purposes and is not a substitute for individual medical advice; treatment decisions should be made in consultation with a physician.